# Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea

> **NCT02651740** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Rifaximin
- **PROCEDURE:** Fecal microbiota transplantation

## Key facts

- **NCT ID:** NCT02651740
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2023-07
- **Final completion:** 2023-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02651740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02651740, "Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02651740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*